McCarthy Asset Management’s Paratek Pharmaceuticals, Inc. PRTK Stock Holding History

McCarthy Asset Management’s Portfolio PRTK Stock Details PRTK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-800	Closed	-$2K	–	328
2022 Q1	$2K	Hold	800	–	–	﹤0.01%	305
2021 Q4	$4K	Buy	800 +200	+33%	+$949	﹤0.01%	223
2021 Q3	$3K	Hold	600	–	–	﹤0.01%	261
2021 Q2	$4K	Hold	600	–	–	﹤0.01%	275
2021 Q1	$4K	Hold	600	–	–	﹤0.01%	243
2020 Q4	$4K	Buy	+600	New	+$3.53K	﹤0.01%	218

Other funds holding PRTK

ACM

AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

OFM

Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return

GAI

General American Investors New York $1.52B AUM 37.94% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Bruce & Co Chicago, Illinois $350M AUM 33.5% 1-Year Est. Return

WVP

Worth Venture Partners Fort Lee, New Jersey $31.6M AUM 28.5% 1-Year Est. Return

Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

FIG

Fortress Investment Group New York $394M AUM 22.99% 1-Year Est. Return

McCarthy Asset Management's PRTK Position: Q2 2022 in Review

McCarthy Asset Management sold out of Paratek Pharmaceuticals, Inc. (PRTK) in Q2 2022, closing a stake of 800 shares — an estimated $2K sold.

McCarthy Asset Management first reported a position in PRTK in Q4 2020 and held it in 6 quarters. The position peaked at $4K in Q4 2021. 84 funds tracked by Wall St. Rank hold PRTK as of Q2 2022.

McCarthy Asset Management reported no remaining Paratek Pharmaceuticals, Inc. position as of Q2 2022 after selling out during the quarter.
McCarthy Asset Management sold 800 Paratek Pharmaceuticals, Inc. shares in Q2 2022, an estimated $2K.
McCarthy Asset Management first reported a position in Paratek Pharmaceuticals, Inc. in Q4 2020 and held it in 6 quarters.
McCarthy Asset Management's Paratek Pharmaceuticals, Inc. position peaked at $4K in Q4 2021.
84 funds tracked by Wall St. Rank held Paratek Pharmaceuticals, Inc. as of Q2 2022.

Based on McCarthy Asset Management's 13F filing for Q2 2022, filed 20 Jul 2022.